Merck & Co., Inc.
Merck Subsidiary Completes €3.4 Billion Notes Offering
Summary
On May 30, 2024, MSD Netherlands Capital B.V., a wholly-owned subsidiary of Merck & Co., Inc., completed an underwritten public offering of €3.4 billion aggregate principal amount of various notes due between 2032 and 2054. The notes are fully and unconditionally guaranteed on an unsecured senior basis by Merck & Co., Inc. and are issued under an indenture dated May 30, 2024. The proceeds from the offering will be used for general corporate purposes.
Profitelligence Alerts
Get alerts for MRK
Be first to know when Merck & Co., Inc. files with the SEC.
Filing Categories
Exhibits (7)
Advertisement
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Official SEC Documents
Advertisement